| Patient | Nelson Mandela |
|---|---|
| Date of birth | 1918-07-18 |
| Identifiers | MRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718 |
| Document date | 2026-11-01 |
| Author | Thandiwe Mokoena, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral. Concerns: Wants to understand a new diagnosis of prostate cancer after a rising PSA, and what treatment would mean at his age and with his commitments; Wants to keep his travel and public work going during treatment. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide | One tablet once daily for four weeks | Oral route | 2001-04-14 to 2001-05-12 | completed | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy | One injection every twelve weeks, two doses | Intramuscular route | 2001-04-21 to 2001-10-06 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2001-04-14 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth once daily after the evening meal, for urinary frequency during radiotherapy | One capsule once daily in the evening | Oral route | 2001-08-18 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Multiparametric MRI of the prostate: gland volume 28 mL with a resection defect from the earlier operation; 9 mm PI-RADS 4 lesion in the left peripheral zone at the mid-gland; no extraprostatic extension, seminal vesicle invasion, or enlarged pelvic nodes | 2001-01-20 to 2001-01-20 | completed | S |
| MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+3 (Grade Group 3) in 1 of 2 targeted cores (30 percent of the core) and in 2 of 12 systematic cores (Gleason 3+4, 10 and 15 percent); 3 of 14 cores in all; no perineural invasion | 2001-02-10 to 2001-02-10 | completed | S |
| Gallium-68 PSMA PET/CT for staging: uptake only in the left peripheral zone of the prostate; no nodal, bone, or visceral disease (N0 M0) | 2001-03-31 to 2001-03-31 | completed | S |
| Transperineal insertion of three gold fiducial markers into the prostate for image guidance, with planning CT and MRI | 2001-07-07 to 2001-07-07 | completed | S |
| Image-guided intensity-modulated radiotherapy to the prostate and proximal seminal vesicles, 74 Gy in 37 daily fractions over about seven and a half weeks, with curative intent; no pelvic nodal radiation | 2001-07-24 to 2001-09-14 | completed | S |
| Advance care planning conversation, about 20 minutes | 2001-06-09 to 2001-06-09 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2000-10-21 | High-dose influenza vaccine, last season | completed | S |
| 1994-05-14 | Tdap vaccine | completed | S |
| 2001-10-27 | High-dose influenza vaccine, this season | completed | S |
| 2001-06-09 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2001-06-09 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1985 | Operation on the prostate for an enlarged gland causing urinary blockage, with part of the gland removed (type of operation not recorded in the cited sources) | D (CLM-0003) |
| 12 August 1988 | Tuberculosis, diagnosed after admission to hospital and treated | D (CLM-0004) |
| November 2000 | Raised PSA found on routine monitoring, followed by a prostate biopsy | D (CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Wants to understand a new diagnosis of prostate cancer after a rising PSA, and what treatment would mean at his age and with his commitments | active | S |
| Wants to keep his travel and public work going during treatment | current | S |
Most recent measures: Prostate specific Ag [Mass/volume] in Serum or Plasma 0.4 on 2001-10-27; Testosterone [Mass/volume] in Serum or Plasma 38 on 2001-10-27; Hemoglobin [Mass/volume] in Blood 14.1 on 2001-03-10; Leukocytes [#/volume] in Blood by Automated count 5.8 on 2001-03-10; Platelets [#/volume] in Blood by Automated count 226 on 2001-03-10; Sodium [Moles/volume] in Serum or Plasma 140 on 2001-03-10; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2001-03-10; Glucose [Mass/volume] in Serum or Plasma 94 on 2001-03-10; Creatinine [Mass/volume] in Serum or Plasma 1.08 on 2001-03-10; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M 69 on 2001-03-10; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2001-03-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 2001-03-10; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 74 on 2001-03-10; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2001-03-10; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2001-03-10; Cholesterol [Mass/volume] in Serum or Plasma 184 on 2001-03-10; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 2001-03-10; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 on 2001-03-10; Triglyceride [Mass/volume] in Serum or Plasma 98 on 2001-03-10; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2001-07-14; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2001-03-10; International Prostate Symptom Score [IPSS] 12 on 2001-10-27; DXA Femur [T-score] Bone density -1.4 on 2001-04-14; DXA Lumbar spine [T-score] Bone density -0.6 on 2001-04-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2001-06-09; Total score [Mini-Cog] 5 on 2001-06-09; Total score [AUDIT-C] 0 on 2001-06-09 [S]
Strengths and supports: Supports: family, close friends, and a personal assistant who manages his schedule [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed | Z79.899 | S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |
| Personal history of external beam radiotherapy to the prostate | active | confirmed | Z92.3 | S — Synthetic: recorded after the course of radiotherapy finished. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2001-03-10 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.4 | ng/mL | <=4 ng/mL | High | S |
| 2001-03-10 | Testosterone [Mass/volume] in Serum or Plasma | 412 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Normal | S |
| 2001-03-10 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2001-03-10 | Leukocytes [#/volume] in Blood by Automated count | 5.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2001-03-10 | Platelets [#/volume] in Blood by Automated count | 226 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2001-03-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2001-03-10 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2001-03-10 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2001-03-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2001-03-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M | 69 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2001-03-10 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2001-03-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-55 U/L | Normal | S |
| 2001-03-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 74 | U/L | 40-129 U/L | Normal | S |
| 2001-03-10 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2001-03-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2001-03-10 | Cholesterol [Mass/volume] in Serum or Plasma | 184 | mg/dL | <=200 mg/dL | Normal | S |
| 2001-03-10 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 2001-03-10 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | <=129 mg/dL | Normal | S |
| 2001-03-10 | Triglyceride [Mass/volume] in Serum or Plasma | 98 | mg/dL | <=149 mg/dL | Normal | S |
| 2001-03-10 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 26 | ng/mL | 30-100 ng/mL | Low | S |
| 2001-03-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2001-03-10 | International Prostate Symptom Score [IPSS] | 7 | {score} | S | ||
| 2001-04-14 | DXA Femur [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2001-04-14 | DXA Lumbar spine [T-score] Bone density | -0.6 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Normal | S |
| 2001-04-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2001-07-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.9 | ng/mL | <=4 ng/mL | Normal | S |
| 2001-07-14 | Testosterone [Mass/volume] in Serum or Plasma | 18 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 2001-07-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2001-07-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2001-10-27 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.4 | ng/mL | <=4 ng/mL | Normal | S |
| 2001-10-27 | Testosterone [Mass/volume] in Serum or Plasma | 38 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 2001-10-27 | International Prostate Symptom Score [IPSS] | 12 | {score} | S | ||
| 2001-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2001-06-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2001-06-09 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2001-06-09 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2001-03-10 | Body height | 183 | cm | S |
| 2001-03-10 | Body weight | 80.2 | kg | S |
| 2001-03-10 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 2001-03-10 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2001-03-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2001-03-10 | Heart rate | 68 | /min | S |
| 2001-03-10 | Respiratory rate | 14 | /min | S |
| 2001-03-10 | Body temperature | 36.6 | Cel | S |
| 2001-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2001-04-14 | Body height | 183 | cm | S |
| 2001-04-14 | Body weight | 80.4 | kg | S |
| 2001-04-14 | Body mass index (BMI) [Ratio] | 24 | kg/m2 | S |
| 2001-04-14 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2001-04-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2001-04-14 | Heart rate | 66 | /min | S |
| 2001-04-14 | Respiratory rate | 14 | /min | S |
| 2001-04-14 | Body temperature | 36.7 | Cel | S |
| 2001-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2001-07-14 | Body height | 183 | cm | S |
| 2001-07-14 | Body weight | 81.6 | kg | S |
| 2001-07-14 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2001-07-14 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2001-07-14 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2001-07-14 | Heart rate | 70 | /min | S |
| 2001-07-14 | Respiratory rate | 14 | /min | S |
| 2001-07-14 | Body temperature | 36.6 | Cel | S |
| 2001-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2001-10-27 | Body height | 183 | cm | S |
| 2001-10-27 | Body weight | 81.4 | kg | S |
| 2001-10-27 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2001-10-27 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2001-10-27 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2001-10-27 | Heart rate | 68 | /min | S |
| 2001-10-27 | Respiratory rate | 14 | /min | S |
| 2001-10-27 | Body temperature | 36.7 | Cel | S |
| 2001-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2001-06-09 | Body height | 183 | cm | S |
| 2001-06-09 | Body weight | 81 | kg | S |
| 2001-06-09 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 2001-06-09 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2001-06-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2001-06-09 | Heart rate | 68 | /min | S |
| 2001-06-09 | Respiratory rate | 14 | /min | S |
| 2001-06-09 | Body temperature | 36.6 | Cel | S |
| 2001-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2001-03-10 | First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral | finished | S |
| 2001-04-14 | Five-week follow-up with radiation oncology consultation: staging result, shared decision on treatment, start of androgen deprivation, and bone density | finished | S |
| 2001-07-14 | Three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effects | finished | S |
| 2001-10-27 | Follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance plan | finished | S |
| 2001-06-09 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivation | completed | GL-AUA-ASTRO-PCA-2022-I, GL-NCCN-PROSTATE-2026 | S |
| Staging for unfavorable intermediate-risk disease with PSMA PET/CT | completed | GL-NCCN-PROSTATE-2026, GL-CMID-2026 | S |
| Treatment chosen through shared decision-making: image-guided external beam radiotherapy to the prostate with six months of androgen deprivation (leuprolide, with bicalutamide for the first four weeks) | completed | GL-AUA-ASTRO-PCA-2022-I, GL-AUA-ASTRO-PCA-2022-III, GL-NCCN-PROSTATE-2026 | S |
| Androgen deprivation monitoring: testosterone, PSA, blood pressure, glucose and lipids, DXA at baseline and every one to two years, vitamin D and calcium, hot flashes, mood, and cognition | completed | GL-CMID-2026, GL-ACS-PCA-SURV-2014 | S |
| After radiotherapy: PSA every six months for five years, then yearly, with recurrence defined as a rise of 2 ng/mL above the nadir (Phoenix); urinary and bowel symptoms at every visit | completed | GL-CMID-2026, GL-NCCN-PROSTATE-2026, GL-ACS-PCA-SURV-2014 | S |
| Distress screening at each visit, physical activity, and a written survivorship care plan | completed | GL-ACS-PCA-SURV-2014, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Reach an informed, shared decision on treatment after hearing every reasonable option, including observation | 2001-04-14 | completed | Radiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation | S |
| Complete six months of androgen deprivation and the course of radiotherapy with side effects managed | 2001-10-27 | completed | Two leuprolide depots and 37 fractions completed; testosterone castrate on treatment; mild hot flashes and urinary frequency, managed | S |
| Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise | 2001-07-14 | completed | Femoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking daily | S |
| PSA falling after radiotherapy, with a written surveillance plan | 2001-10-27 | completed | PSA 0.4 ng/mL six weeks after radiotherapy; PSA every six months planned | S |